NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NYSE · WST · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
West Pharmaceutical Services, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.93% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
West Pharmaceutical Services, Inc.’s forward annual dividend is $0.88 per share, paid quarterly. The forward yield is 0.21% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
West Pharmaceutical Services, Inc.’s next earnings report is currently expected on Feb 11, 2027, with estimated earnings per share of $2.26. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow West Pharmaceutical Services, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 | Jul 24, 2025 | $1.84+21.85% vs estimate | $766.20M+5.52% vs estimate |
|---|
| Q1 2025 | Apr 24, 2025 | $1.45+18.85% vs estimate | $698.00M-2.1% vs estimate |
|---|
| Q4 2024 | Feb 13, 2025 | $1.82+6.43% vs estimate | $748.80M+1.12% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
17 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 6 contributors · Median target $420.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
€228.40+€7.00 (+3.16%)
Sartorius Stedim Biotech S.A.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
€298.50+€6.00 (+2.05%)
Sartorius AG’s quoted price sits in the upper half of its reported 52-week range, 0.27% below the high.
$130.64+$3.47 (+2.73%)
AptarGroup, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.07% below the high.
$20.24+$0.81 (+4.17%)
Stevanato Group S.p.A.’s quoted price sits in the upper half of its reported 52-week range, 25.04% below the high.
$168.65+$2.26 (+1.36%)
ICU Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.55% below the high.
$38.61$0.00 (0.0%)
BioLife Solutions, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.89% below the high.
